| Literature DB >> 22618883 |
Richmond T Prehn1, Liisa M Prehn.
Abstract
Increasing evidence has shown that probably all malignant mouse cells, even those of spontaneous sporadic cancers, are endowed with tumor-specific antigens. Stimulation of cancer growth, rather than inhibition by the immune reaction, is seemingly the prevalent effect in the animal of origin (the autochthonous animal). Small initial dosages of even strong tumor antigens tend to produce stimulatory immune reactions rather than tumor inhibition in any animal. Thus, an immune response at a low level may be an essential growth-driving feature of nascent cancers, and this may be why all cancers apparently have tumor-specific antigens. Inasmuch as a low level of immunity is stimulatory to tumor growth while larger dosages are inhibitory, immuno-selection via this low response may tend to keep the antitumor immune reaction weak and at a nearly maximal stimulatory level throughout most of a tumor's existence. These facts suggest that both suppression of tumor immunity and a heightened immune reaction might each be therapeutic although very contrasting modalities.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22618883 PMCID: PMC3378832 DOI: 10.1007/s00262-012-1233-5
Source DB: PubMed Journal: Cancer Immunol Immunother ISSN: 0340-7004 Impact factor: 6.968
Fig. 1The IRC or immune reaction curve. Idealized depiction of the data from [6] showing the shape of the immune reaction curve or IRC. The letters and numerals are arbitrary aids to discussion